top of page

South Africa's SAPHRA: Validation Template For ECTD Variation Applications, QOA & QIS

Recently (05 May 2023) the South African Health Products Regulatory Authority (SAPHRA) released the template "Validation Template For ECTD Variation Applications", For "Module 2.3 Quality Overall Summary (QOS)" and "For Module 2.3 Quality Information Summary (QIS)".

SAPHRA’s Validation Template For ECTD Variation Applications is a document that provides guidance on how to validate electronic submissions of variation applications for human medicines in South Africa.


An application's Validation Template allows SAHPRA to verify that all required information has been provided when evaluating a variation application submitted in eCTD format for a medicinal product for human use. It contains information on the validation criteria, the validation process, the validation report, and the validation checklist.


It is also used for follow-up sequences that may be required for the variation and the applicant must ensure that all relevant fields are completed.


The implementation date is 15 May 2023.


Similar to the validation template, Module 2.3 Quality Overall Summary (QOS) document is for use in all products including Biologics and veterinary products, where the information is not applicable for the specific molecule it is suggested to indicate “N/A” and Module 2.3 Quality Information Summary (QIS) should be completed to provide a condensed summary of the key quality information for applications containing APIs of synthetic, semi-synthetic or biological origin.

Recent Posts

See All

1 Comment


Lily Parker
Lily Parker
Oct 18, 2024

This is great information, especially for those involved in regulatory affairs in South Africa. The release of SAPHRA's Validation Template for eCTD Variation Applications is a step forward in streamlining the process and ensuring that all necessary information is accurately captured for human medicinal products. It’s particularly useful to know that it applies not just to standard pharmaceuticals but also to biologics and veterinary products, with clear guidance on handling non-applicable information. This will definitely help applicants stay organized and avoid potential delays during the validation process. Thanks for sharing such a detailed update!

Like
I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page